Adelphi Real World, Bollington, Macclesfield, United Kingdom.
Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
Clin Ther. 2019 Feb;41(2):205-220. doi: 10.1016/j.clinthera.2018.12.004. Epub 2018 Dec 31.
Chronic idiopathic urticaria (CIU) is a debilitating skin condition that can profoundly affect patients' quality of life. This study explored the impact of refractory and nonrefractory CIU on patients in the real-world setting in the United States.
Data were collected from the Adelphi Real World 2015 Urticaria Disease-Specific Programme. Physicians completed patient record forms (PRFs) for 4 consecutive patients consulting with nonrefractory CIU and 6 patients with refractory CIU. The PRF included information on patient characteristics, medication, and disease severity; physicians were asked about the impact of CIU on patients, and to rate their satisfaction with patients' treatment (scale, 1-7 [1 = extremely dissatisfied and 7 = extremely satisfied]). The same patients were asked to complete a patient self-completion form (PSC). This included questions regarding how CIU affected their everyday life and their satisfaction with and understanding of their condition and medications. The PSC included a number of patient-reported outcomes measures: the Dermatology Life Quality Index (scored from 0 to 30, with higher scores indicating greater impact), the Work Productivity and Activity Impairment (4 scores calculated [absenteeism, presenteeism, work productivity loss, and activity impairment], each scored from 0% to 100% after transformation, with higher scores indicating greater impairment), and the Jenkins Sleep Scale (assessed over 30 days; scored from 0 to 20, with higher scores indicating greater sleep disturbance). Completion of the PSC was voluntary.
Seventeen physicians completed a total of 184 PRFs (108 for patients with refractory CIU; 76 for those with nonrefractory CIU); 140 of these 184 patients completed a PSC form (93 with refractory CIU; 47 with nonrefractory CIU). Overall, 26% of the entire population (30% of patients with refractory CIU and 17% with nonrefractory CIU) reported that skin symptoms had a great effect on their lives (Dermatology Life Quality Index score ≥11). Sleep problems were common: mean Jenkins Sleep Scale scores were 7.8 overall (8.1 for patients with refractory CIU and 7.2 for those with nonrefractory CIU). Overall work impairment was 19% in the overall population, with similar values in refractory and nonrefractory patients (18% and 20%, respectively). Physician satisfaction with disease control was not high, with physicians reporting a mean score of 4.8 on a 7-point scale. Twenty-one percent of patients were extremely dissatisfied, very dissatisfied, or dissatisfied with their treatment, and 52% believed better control could be achieved.
The humanistic burden of CIU is high. There is clearly a need for better management of CIU to improve outcomes for patients.
慢性特发性荨麻疹(CIU)是一种使人虚弱的皮肤病,会严重影响患者的生活质量。本研究旨在探讨美国真实世界中难治性和非难治性 CIU 对患者的影响。
数据来自 Adelphi 真实世界 2015 年荨麻疹疾病专项研究。医生为连续 4 例非难治性 CIU 患者和 6 例难治性 CIU 患者填写患者病历表(PRF)。PRF 包括患者特征、用药和疾病严重程度等信息;医生被问及 CIU 对患者的影响,并对患者治疗的满意度进行评分(1-7 分[1 表示非常不满意,7 表示非常满意])。同一批患者被要求填写一份患者自我评估表(PSC)。PSC 包含有关 CIU 如何影响他们日常生活、他们对自身状况和药物的满意度和理解程度的问题。PSC 包含了一些患者报告的结果测量指标:皮肤病生活质量指数(评分范围为 0-30 分,分数越高表示影响越大)、工作效率和活动障碍(4 项评分计算[缺勤、在职病假、工作效率损失和活动障碍],每项评分在转换后均为 0%-100%,分数越高表示障碍越大)和詹金斯睡眠量表(评估 30 天;评分范围为 0-20 分,分数越高表示睡眠障碍越严重)。PSC 的填写是自愿的。
17 名医生共完成了 184 份 PRF(难治性 CIU 患者 108 份,非难治性 CIU 患者 76 份);其中 140 名患者完成了 PSC 表(难治性 CIU 患者 93 份,非难治性 CIU 患者 47 份)。总体而言,26%的人群(难治性 CIU 患者中 30%,非难治性 CIU 患者中 17%)报告皮肤症状对他们的生活有很大影响(皮肤病生活质量指数评分≥11)。睡眠问题很常见:整体詹金斯睡眠量表评分为 7.8 分(难治性 CIU 患者为 8.1 分,非难治性 CIU 患者为 7.2 分)。总体工作障碍在人群中为 19%,难治性和非难治性患者的数值相似(分别为 18%和 20%)。医生对疾病控制的满意度不高,医生在 7 分制上的平均得分为 4.8 分。21%的患者对治疗非常不满意、不满意或不满意,52%的患者认为可以达到更好的控制效果。
CIU 的人文负担很高。显然,需要更好地管理 CIU,以改善患者的治疗效果。